Objective：To investigate the efficacy of micturition induction therapy (MIT) for recovery of urinary continence in stroke patients without uresiesthesia.
Methods：We retrospectively examined the efficacy of MIT for recovery of continence in stroke patients without uresiesthesia and assessed improvement in the Functional Independence Measure (FIM) score in 201 stroke patients admitted to our rehabilitation hospital.
Results：Of the 201 patients, 160 had uresiesthesia. The 41 patients without uresiesthesia were significantly older and had lower FIM scores on admission than those with uresiesthesia. Of 41 patients without uresiesthesia, 15 received MIT. There was no difference between the groups in terms of age or FIM scores on admission. Nine of 15 (60％) patients who received MIT recovered continence, whereas only 7 of 26 (26.7％) who did not receive MIT recovered continence. MIT was significantly effective for recovery of continence in patients without uresiesthesia (p ＜0.05). The gain in FIM scores was significantly higher in patients who recovered continence than in those who did not recover continence, irrespective of whether MIT was provided (p 0.05).
Conclusion：MIT was effective for recovery of uresiesthesia and continence in patients without uresiesthesia after stroke.

PURPOSE: Nasal polyposis is a chronic inflammatory disease of the upper airways often associated with asthma and characterized by markedly increased numbers of eosinophils, Th2 type lymphocytes, fibroblasts, goblet cells and mast cells. Previous studies have shown elevated levels of thymic stromal lymphopoietin (TSLP) in atopic diseases like asthma, atopic dermatitis and mainly in animal models of allergic rhinitis (AR). Here, we investigated the expression of TSLP in nasal polyps from atopics and non-atopics in comparison with the nasal mucosa and its potential role in nasal polyposis. METHODS: Messenger RNA expression for TSLP, thymus and activation-regulated chemokine (TARC) and macrophage derived chemokine (MDC) in nasal polyps and nasal mucosa of atopics and non-atopics was analyzed by real time PCR. Immunoreactivity for TSLP in nasal polyps and in the nasal mucosa of patients with AR and non-allergic rhinitis (NAR) was analyzed by immunohistochemistry. Eosinophil counts was analyzed by Wright-Giemsa staining and nasal polyp tissue IgE, by ELISA. RESULTS: Messenger RNA expression for TSLP,TARC and MDC was markedly higher in nasal polyps as compared to the allergic nasal mucosa. Immunoreactivity for TSLP was detected in epithelial cells, endothelial cells, fibroblasts and inflammatory cells of the nasal mucosa and nasal polyps. The number of TSLP+ cells was significantly greater in the nasal mucosa of AR than NAR patients. The number of TSLP+ cells in nasal polyps from atopics was significantly greater than that of non-atopics and that in the allergic nasal mucosa. The number of TSLP+ cells correlated well with the number of eosinophils and the levels of IgE in nasal polyps. CONCLUSIONS: The high expression of TSLP in nasal polyps and its strong correlation to eosinophils and IgE suggest a potential role for TSLP in the pathogenesis of nasal polyps by regulating the Th2 type and eosinophilic inflammation.
Asthma ; Chemokine CCL17 ; Chemokine CCL22 ; Cytokines ; Dermatitis, Atopic ; Endothelial Cells ; Eosinophils ; Epithelial Cells ; Fibroblasts ; Goblet Cells ; Humans ; Immunoglobulin E ; Immunohistochemistry ; Inflammation ; Lymphocytes ; Mast Cells ; Models, Animal ; Nasal Mucosa ; Nasal Polyps ; Real-Time Polymerase Chain Reaction ; Rhinitis ; Rhinitis, Allergic, Perennial ; RNA, Messenger